Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.